世界科学技术-中医药现代化
世界科學技術-中醫藥現代化
세계과학기술-중의약현대화
WORLD SCIENCE AND TECHNOLOGY-MODERNIZATION OF TRADITIONAL CHINESE MEDICINE
2014年
1期
109-111
,共3页
抗纤益心方%扩张型心肌病%左室舒张末内径%左房内径%射血分数%缩短分数
抗纖益心方%擴張型心肌病%左室舒張末內徑%左房內徑%射血分數%縮短分數
항섬익심방%확장형심기병%좌실서장말내경%좌방내경%사혈분수%축단분수
Kang-Xian Yi-Xin formula%dilated cardiomyopathy%left ventricular end diastolic diameter%left atrial diameter%ejection fraction%fractional shortening
目的：观察抗纤益心方对扩张型心肌病患者心脏大小及心功能的影响。方法：将85例患者随机分为治疗组43例，对照组42例（死亡1例），两组均进行常规西药治疗，此外治疗组加服抗纤益心方汤剂，日1剂。6个月后观察超声左室舒张末内径、左房内径、射血分数及缩短分数变化。结果：两组均能减少左室舒张末内径、左心房内径，尤以治疗组明显（P约0.05），两组在治疗后左室舒张末内径具有明显差异（P约0.05）。两组在射血分数、缩短分数方面均有明显提高，治疗组在治疗前后具有显著差异（P约0.01），且治疗后组间差异有统计学意义（P约0.05）。结论：抗纤益心方能减少扩张型心肌病患者左室舒张末内径、左房内径，提高射血分数及缩短分数，改善患者心脏功能。
目的：觀察抗纖益心方對擴張型心肌病患者心髒大小及心功能的影響。方法：將85例患者隨機分為治療組43例，對照組42例（死亡1例），兩組均進行常規西藥治療，此外治療組加服抗纖益心方湯劑，日1劑。6箇月後觀察超聲左室舒張末內徑、左房內徑、射血分數及縮短分數變化。結果：兩組均能減少左室舒張末內徑、左心房內徑，尤以治療組明顯（P約0.05），兩組在治療後左室舒張末內徑具有明顯差異（P約0.05）。兩組在射血分數、縮短分數方麵均有明顯提高，治療組在治療前後具有顯著差異（P約0.01），且治療後組間差異有統計學意義（P約0.05）。結論：抗纖益心方能減少擴張型心肌病患者左室舒張末內徑、左房內徑，提高射血分數及縮短分數，改善患者心髒功能。
목적：관찰항섬익심방대확장형심기병환자심장대소급심공능적영향。방법：장85례환자수궤분위치료조43례，대조조42례（사망1례），량조균진행상규서약치료，차외치료조가복항섬익심방탕제，일1제。6개월후관찰초성좌실서장말내경、좌방내경、사혈분수급축단분수변화。결과：량조균능감소좌실서장말내경、좌심방내경，우이치료조명현（P약0.05），량조재치료후좌실서장말내경구유명현차이（P약0.05）。량조재사혈분수、축단분수방면균유명현제고，치료조재치료전후구유현저차이（P약0.01），차치료후조간차이유통계학의의（P약0.05）。결론：항섬익심방능감소확장형심기병환자좌실서장말내경、좌방내경，제고사혈분수급축단분수，개선환자심장공능。
This study was aimed to observe the influence of Kang-Xian Y i-Xin (KXYX) formula on the heart size and cardiac function of patients with dilated cardiomyopathy (DCM). A total of 85 cases were randomly divided into the treatment group (43 cases) and the control group (42 cases, with 1 death case). Both groups were treated with routine western medicine. And the KXYX formula was combined in the treatment group once a day. Six months later, changes of the left ventricular end diastolic diameter (LVEDD), left atrial diameter (LAd), ejection fraction (EF) and fractional shortening (FS) were observed by ultrasonography. The results showed that both groups can reduce the LVEDD and Lad. And the effect was obvious in the treatment group (P< 0.05). There was significant difference in the LVEDD of both groups after treatment (P< 0.05). The EF and FS were raised obviously in both groups. There was significant difference before and after treatment in the treatment group (P < 0.01). There was statistical differ-ence between groups after treatment (P< 0.05). It was concluded that the KXYX formula can decrease the LVEDD, Lad, enhance EF and FS, in order to promote the cardiac function of patients with DCM.
